Cannabis and Depression: Promising Animal Findings, Limited Evidence in People
Cannabis is sometimes promoted as a treatment for depression, but the evidence does not yet support that conclusion. Research on cannabis compounds has produced intriguing findings in animals and short-term studies of anxiety, while human evidence for treating depressive disorders remains limited and inconsistent.
Cannabis contains many cannabinoids, including tetrahydrocannabinol (THC), the compound primarily responsible for intoxication, and cannabidiol (CBD), which does not produce a typical “high.” These substances do not affect the brain in identical ways, so findings about CBD should not automatically be applied to marijuana or THC-containing products as a whole.
Depression is a serious condition involving persistent low mood or loss of interest, along with possible changes in sleep, appetite, energy, concentration, and feelings of worthlessness or hopelessness. Effective treatment may include psychotherapy, medication, or a combination of approaches. The National Institute of Mental Health describes psychotherapy as an evidence-based treatment for depression and other mental health conditions.
Some of the most encouraging cannabis-related findings come from preclinical research. For example, a study of CBD in mice and rats reported antidepressant-like effects under certain experimental conditions. However, the results varied by species, strain, sex, dose, and timing. The animals were also assessed with behavioral tests that model aspects of depression; those tests cannot establish that CBD treats clinical depression in people. The study of CBD’s strain-, sex-, and time-dependent effects therefore offers a basis for further research, not proof of a human antidepressant effect.
Research on anxiety helps explain why some people may report feeling better after using cannabis or CBD. In a small, double-blind study involving 10 people with generalized social anxiety disorder, a single dose of CBD was associated with lower self-reported anxiety than placebo. The study was preliminary, involved a very small sample, and examined CBD rather than ordinary cannabis. A later review found that CBD’s effects may depend on dose, with THC reducing anxiety at some lower doses but increasing it at higher doses. More and larger clinical trials are needed.
Evidence from broader human research is more cautious. A 2024 systematic review of studies on cannabis use and mood disorders found that cannabis use was associated with more depressive symptoms, a greater likelihood of developing major depressive disorder, and a less favorable course of mood disorders. Because much of this evidence was observational, it cannot by itself prove that cannabis causes depression: people may use cannabis in response to depression, and factors such as trauma, stress, other substance use, or preexisting mental illness may influence both outcomes. Even so, the findings do not support presenting cannabis as a proven treatment.
A separate updated meta-analysis of longitudinal studies found a modestly higher risk of depression among cannabis users, while emphasizing limitations in the available research. The authors noted that patterns of use, dose, frequency, and long-term effects remain important unanswered questions. Short-term reports that cannabis improves mood also may not reflect sustained improvement in depressive symptoms or recovery from a depressive disorder.
Cannabis can also create risks that are especially relevant to people experiencing depression or anxiety. THC may impair memory, attention, judgment, coordination, and reaction time, and using cannabis can make driving unsafe. Cannabis use has also been linked with depression, social anxiety, psychosis, suicidal thoughts, and suicide attempts, although researchers are still working to distinguish cause from correlation. The Centers for Disease Control and Prevention summarizes the known links between cannabis and mental health.
Frequent or high-dose use can lead to cannabis use disorder, making it difficult to cut back or stop despite psychological, social, or health-related problems. Products with high THC concentrations may carry additional risks, and a person’s response can vary according to dose, product composition, personal history, and vulnerability to mental illness.
Overall, laboratory and animal studies suggest that individual cannabinoids—particularly CBD—may have biological effects relevant to mood and anxiety. But those findings should not be confused with evidence that marijuana treats depression. Current clinical evidence is insufficient to recommend cannabis as a first-line treatment, and cannabis should not replace an assessment by a qualified health professional. Anyone with persistent depressive symptoms should discuss evidence-based options with a clinician, particularly before using cannabis alongside antidepressants or other medications.
